Back to Search Start Over

Inhibiting BTB domain and CNC homolog 1 (Bach1) as an alternative to increase Nrf2 activation in chronic diseases

Authors :
Denise, Mafra
Livia, Alvarenga
Ludmila F M F, Cardozo
Milena B, Stockler-Pinto
Lia S, Nakao
Peter, Stenvinkel
Paul G, Shiels
Source :
Biochimica et Biophysica Acta (BBA) - General Subjects. 1866:130129
Publication Year :
2022
Publisher :
Elsevier BV, 2022.

Abstract

BTB and CNC homology 1 (Bach1) is a protein that forms nuclear heterodimers with the small musculoaponeurotic fibrosarcoma (sMaf). These bind to genomic DNA, promoting the inhibition of the synthesis of a range of antioxidant enzymes. This heterodimer antagonises the actions of nuclear factor erythroid 2-related factor-2 (Nrf2), a master regulator of cytoprotective responses in the cells. Studies have shown that Nrf2 expression is downregulated and Bach1 expression upregulated in many chronic diseases; hence Nrf2 activators and Bach1 inhibitors need to be investigated for their potential to mitigate inflammation and improve antioxidant responses in the chronic burden of lifestyle diseases, including chronic kidney disease. Thus, this review will discuss the status of Bach1 in such diseases and the use of possible inhibitors as a promising therapeutic approach.

Details

ISSN :
03044165
Volume :
1866
Database :
OpenAIRE
Journal :
Biochimica et Biophysica Acta (BBA) - General Subjects
Accession number :
edsair.doi.dedup.....b1c09df2f09c4ef296088cc441723652
Full Text :
https://doi.org/10.1016/j.bbagen.2022.130129